The technology used to develop the Covid vaccine should be used to develop help for colorectal cancer patients. Writes today’s news.
The German company Biontech, which developed the first approved mRNA vaccine against covid-19 in cooperation with the company Pfizer, has launched phase two studies of a vaccine based on the same technology that will have the task of teaching the immune system to attack cancer cells.
– If this works, we can imagine that the method could also be used in other types of cancer, such as certain types of breast cancer and lung cancer, Biontech CEO Ugur Sahin tells the paper.
The goal is to prevent disease recurrence in patients who have had their lumpectomy, affecting just over a third of all colorectal cancer patients. According to DN, results are expected to be ready in about three years.
The vaccine contains a type of genetic code, a short sequence of messenger RNA – the same sequence the virus uses to make the so-called nail protein, which the virus uses to bind cells. The idea is that the body must learn to recognize this essential protein and create antibodies against it.
“Entrepreneur. Freelance introvert. Creator. Passionate reader. Certified beer ninja. Food nerd.”